Francesco De Rubertis
CIK 1601521 · last filed 2026-06-24
Francesco De Rubertis is a corporate insider who has filed 11 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$15.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NERV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
COURS DE RIVE 10
GENEVA CH-1204
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Director | 0 | $40.50 | $0 | $14.43M | 6 | 2026-06-24 |
| NERV | Director | 586,363 | $2.12 | $1.24M | $699.7K | 4 | 2016-12-14 |
| Aravive, Inc. (VSAR) Delisted | Director | — | — | — | $0 | 1 | 2014-03-24 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| CNTA | Medicxi Secondary Co-Invest I LP See footnote |
0 | — | 2026-06-24 |
| Total | 0 | |||
| NERV | Index Ventures III See Footnotes |
586,363 | 100.0% | 2016-12-14 |
| Total | 586,363 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | −19,963,157 | $0 | EDGAR |
| 2022-03-23 | Centessa Pharmaceuticals plc (CNTA) Delisted | Other (J) | +1,839,265 | $0 | EDGAR |
| 2021-12-06 | Centessa Pharmaceuticals plc (CNTA) Delisted | Buy (P) | +34,326 | $440.1K | EDGAR |
| 2021-12-02 | Centessa Pharmaceuticals plc (CNTA) Delisted | Buy (P) | +97,151 | $1.19M | EDGAR |
| 2021-11-30 | Centessa Pharmaceuticals plc (CNTA) Delisted | Buy (P) | +68,523 | $797.4K | EDGAR |
| 2021-06-04 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | +2,531,818 | $12.00M | EDGAR |
| 2016-12-14 | NERV | Exer (X) | +202,634 | $1.17M | EDGAR |
| 2016-08-12 | NERV | Sell (S) | −1,000,000 | -$10.00M | EDGAR |
| 2015-03-20 | NERV | Buy (P) | +202,634 | $974.7K | EDGAR |
| 2014-07-09 | NERV | Mixed | +1,796,832 | $10.78M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).